• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Eisai selling off Oncology products

Quote
Anonymous said:
Stop the presses. Eisai is considering selling products that have exceeded their shelf life??? Smart decision. Now we can focus on our core products and use the cash to make up for the lackluster 23 results.

Folks, Eisai is making money. If u want to go elsewhere, that's your prerogative. I'm going to stick around and see what happens.

Remember, six of our seven biggest products exceeded their target last year. we need people that are committed so if you're not, leave. If you are, stay focused on driving results and I think u will be pleased with the results.
Click to expand...

LOL. You wrote, "I'm going to stick around and see what happens."

That's code for I can't get another job so I have no choice but to stay in this crap hole.
 




Anonymous said:
You my friend are GREATLY mistaken. Targretin is Eisai's biggest profit margin by any drug. Ontak and Targretin are still very very viable. Eisai just does not want to participate in the arena that it takes to sell these drugs. ie, selling off of a compendium listing, not indications. These two drugs alone if properly marketed, are enough to sustain any small start-up. Gliadel still profits over $40m and has many pockets of business. The fact is Eisai does not nor wants to learn how to be an effective oncology company. They are selling these off to obtain cash, they need cash flow. So please don't lecture me on your kool-aid.
Click to expand...

Gliadel profits over $40M? Not really. Do you know the difference between gross sales and operating profits? Gliadel is not profitable for many reasons. You must be a slaes rep.
 




Anonymous said:
Stop the presses. Eisai is considering selling products that have exceeded their shelf life??? Smart decision. Now we can focus on our core products and use the cash to make up for the lackluster 23 results.

Folks, Eisai is making money. If u want to go elsewhere, that's your prerogative. I'm going to stick around and see what happens.

Remember, six of our seven biggest products exceeded their target last year. we need people that are committed so if you're not, leave. If you are, stay focused on driving results and I think u will be pleased with the results.
Click to expand...

This has to be Q, MC, or TB. Only those 3 would be dumb enough to still drink the EEEEZAAAI Kool-Aid.
 




















Anonymous said:
Reading helps. The OP spelled them gleadel and lucedra incorrectly.
Click to expand...

Doesn't matter. Eisai has been wanting to sell them since they were acquired. Lucedra was sold to Eisai by MGI as the mega-million product and the best thing in its class. Guess what, Eisai was doomed.

I wonder who is dumber than Eisai to purchase these two products?
 




Anonymous said:
Doesn't matter. Eisai has been wanting to sell them since they were acquired. Lucedra was sold to Eisai by MGI as the mega-million product and the best thing in its class. Guess what, Eisai was doomed.

I wonder who is dumber than Eisai to purchase these two products?
Click to expand...

Never forget this is the company that purchased Colazol. Had a big expensive POA in its honor, then it went gerneric or something a month later.

This company can't do anything right.
 




Anonymous said:
Stop the presses. Eisai is considering selling products that have exceeded their shelf life??? Smart decision. Now we can focus on our core products and use the cash to make up for the lackluster 23 results.

Folks, Eisai is making money. If u want to go elsewhere, that's your prerogative. I'm going to stick around and see what happens.

Remember, six of our seven biggest products exceeded their target last year. we need people that are committed so if you're not, leave. If you are, stay focused on driving results and I think u will be pleased with the results.
Click to expand...

Drink more koolaid - its showing how smart you are
 




Anonymous said:
Doesn't matter. Eisai has been wanting to sell them since they were acquired. Lucedra was sold to Eisai by MGI as the mega-million product and the best thing in its class. Guess what, Eisai was doomed.

I wonder who is dumber than Eisai to purchase these two products?
Click to expand...

Eisai also bought lorcaserin after every other company on the planet passed on it.
 
































Eisai, at the very least, is looking to sell off Ontak(and probably Targretin). I’m no longer at the company but the BD guys at my current company have asked me on several occasions over the last few months about Ontak and flat out told me Eisai is shopping it around.
 




Anonymous said:
Eisai, at the very least, is looking to sell off Ontak(and probably Targretin). I’m no longer at the company but the BD guys at my current company have asked me on several occasions over the last few months about Ontak and flat out told me Eisai is shopping it around.
Click to expand...

Were your guys interested or did they assume it was just another piece of garbage like the rest of the Ayzi portfolio?
 




Similar threads

Why is Eisai having such a hard time selling Belviq
Replies
12
Views
2K
Eisai
Anonymous
Endpoints: Eisai says Alzheimer's drug keeps working after three years. But weaknesses in study raise questions
Replies
8
Views
654
Eisai
anonymous
Eisai and Bristol Myers cancel cancer ADC deal | BioPharma Dive
Replies
4
Views
449
Eisai
anonymous
Fierce Pharma - Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer's fight
Replies
13
Views
1K
Eisai
anonymous
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s | BioSpace
Replies
1
Views
604
Eisai
anonymous
Top Bottom
Back
Quote